Immune Response in 465 Hematological Patients Vaccinated with mRNA Vaccine Against SARS-CoV-2: A Single Centre Experience

Šušol, Ondrej; Hájková, B.; Jelı́nek, Tomáš; Mihályová, Jana; Hradská, Katarína; Kaščák, Michal; Benková, Kateřina; Zelená, Hana; Martínek, Jan; Hájek, Roman

doi:10.2139/ssrn.3960655

SSRN Journal

2021

DOI: 10.2139/ssrn.3960655

|View full text |Cite

Immune Response in 465 Hematological Patients Vaccinated with mRNA Vaccine Against SARS-CoV-2: A Single Centre Experience

Ondrej Šušol

B. Hájková

Tomáš Jelı́nek

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID‐19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic

Šušol,

Šušolová,

Klempíř

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

AimsTo evaluate antibody response to mRNA vaccine, identify subgroups with poor response and to determine long‐term antibody durability in hematological patients.Materials and MethodsWe have vaccinated 292 patients with all hematological malignancies with a third dose of mRNA COMIRNATY vaccine with a 12‐month follow‐up period in our center in Ostrava, Czech Republic.ResultsAntibody response for the whole cohort exceeded 74% through the whole 12‐month follow‐up. Lowest seroconversion was observed in CLL cohort (20/41, 48.8%), patients who received anti‐CD20 therapy < 6 months before vaccination (8/30, 26.7%) and BTK inhibitors (3/6, 50.0%). On the contrary, patients with chronic myeloproliferative neoplasms and acute leukemia performed comparably with healthy population (33/33; 100% and 12/13; 92.3%, respectively). We have seen better results if the time interval between anti‐CD20 therapy and additional vaccine dose was longer than 6 months (5/8 patients achieved seroconversion on 4th booster dose after previous failure). Also, 36 patients received a 4th dose of vaccine as a booster with measurable increase in protective antibodies in 50% (18/36).ConclusionsAdditional doses show promise for a well‐timed revaccination even in poor responders. To our knowledge, no study comparable to our work in terms of follow‐up length, vaccine consistency or variety of hematological malignancies and/or treatment has been reported yet. Our findings shed more light on long‐term antibody response to mRNA vaccines against SARS‐CoV‐2 in patients with hematological cancer and bring important data for the evaluation of possible vaccine failure and scheduling of subsequent doses.

show abstract

One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID‐19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic

Šušol,

Šušolová,

Klempíř

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Immune Response in 465 Hematological Patients Vaccinated with mRNA Vaccine Against SARS-CoV-2: A Single Centre Experience

Cited by 1 publication

References 30 publications

One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID‐19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic

One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID‐19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic

Contact Info

Product

Resources

About